Loading...

Recent search criteria

Media
< Back

Press Releases

Media Statements

Media Library
Our 2023 Integrated Annual Report is live!
Investors
< Back

Investors

Financial Results

Corporate News

Financial Calendar

Investor Events

Reports and Accounts

Regulated Information
Financial results for the first half of 2024

2024 Annual General Meeting
Partnering
Careers
- Careers
- Careers
- Working at Ipsen
- Culture

Loading...
English EN Français FR EN
- EnglishEN
- FrançaisFR
Global
< Back
- Global EN FR
- Annual Report EN FR
United States

Brazil

Canada EN

Canada FR

Australia

China

Singapore

South Korea

Japan

Belgium

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Czech Republic

Switzerland

Home
Company
- Company
- Company
- Leadership
- History
- Fondation Ipsen
Science
- Science
- Oncology
- Rare Disease
- Neuroscience
- Products
- R&D
- Pipeline
- Clinical Trials
Responsibility
- Responsibility
- Responsibility
- Environment
- Patients
- People
- Governance
- Our Standards
Patients
Stories

Home
Leadership
leadership

Michelle Davis

Back

Michelle Davis

Michelle Davis

Share this on social media

IPN price

€103.20

€1.80 (1.78%)

Media
Investors
Partnering
Careers

Company
Responsibility
Patients
Stories

Annual Report
Contact us

Terms and Conditions
Cookie Policy
Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2024

You are now leaving the Ipsen group website. To continue, please click on Continue?